| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
  free 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
  free 
  free 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Improving the use of research evidence in guideline development: 6  Determining  which outcomes are important Schunemann HJ; Oxman AD; Fretheim AHealth Res Policy Syst  2006[Dec]; 4 (ä): 18BACKGROUND: The World Health Organization (WHO), like many other organisations  around the world, has recognised the need to use more rigorous processes to  ensure that health care recommendations are informed by the best available  research evidence. This is the sixth of a series of 16 reviews that have been  prepared as background for advice from the WHO Advisory Committee on Health  Research to WHO on how to achieve this. OBJECTIVES: We reviewed the literature on  determining which outcomes are important for the development of guidelines.  METHODS: We searched five databases of methodological studies for existing  systematic reviews and relevant methodological research. We did not conduct a  complete systematic review ourselves. Our conclusions are based on the available  evidence, consideration of what WHO and other organisations are doing and logical  arguments. KEY QUESTIONS AND ANSWERS: We did not find a systematic review that  addresses any of the following key questions and we found limited relevant  research evidence. What methods should WHO use to identify important outcomes?  Methods of outcome identification should be transparent and explicit. The  consultation process should start with identification of all relevant outcomes  associated with an intervention. Those affected, including consumers, should be  involved in the selection of outcomes. A question driven approach (what is  important?) is preferable to a data driven approach (what data are at hand?) to  identify important outcomes. What type of outcomes should WHO consider and how  should cultural diversity be taken account of in the selection of outcomes?  Desirable (benefits, less burden and savings) and undesirable effects should be  considered in all guidelines. Undesirable effects include harms (including the  possibility of unanticipated adverse effects), greater burden (e.g. having to go  to the doctor) and costs (including opportunity costs). Important outcomes (e.g.  mortality, morbidity, quality of life) should be preferred over surrogate,  indirect outcomes (e.g. cholesterol levels, lung function) that may or may not  correlate with patient important outcomes. Ethical considerations should be part  of the evaluation of important outcomes (e.g. impacts on autonomy). If the  importance of outcomes is likely to vary across cultures, stakeholders from  diverse cultures should be consulted and involved in the selection of outcomes.  How should the importance of outcomes be ranked? Outcomes should be ranked by  relative importance, separated into benefits and downsides. Information from  research on values and preferences should inform the ranking of outcomes whenever  possible. If the importance of outcomes is likely to vary across cultures,  ranking of outcomes should be done in specific settings. If evidence is lacking  for an important outcome, this should be acknowledged, rather than ignoring the  outcome.ä
 |